Meropenem Kabi (Meropenem Trihydrate)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, leading to weakened cell walls, osmotic instability, and ultimately bacterial cell lysis and death.

The specific dose and infusion rate of Meropenem Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local susceptibility patterns. Dosage regimens are individualized and should follow the prescriber’s order.

Safety data for Meropenem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly broader gram‑negative coverage and better stability against many beta‑lactamases compared with imipenem. Choice among carbapenems depends on local resistance patterns, patient renal function, and specific infection site.

Meropenem Kabi must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Once prepared for infusion, use within the time frame recommended by the manufacturer.

Meropenem Kabi is supplied as an injectable solution for intravenous infusion. It is administered by slow IV push or infusion over 15‑30 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

The most serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant renal or hepatic toxicity. Prompt recognition and management are essential.

Meropenem Kabi is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug may exacerbate these conditions.